BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
9.48
-0.21 (-2.17%)
At close: Aug 21, 2026, 4:00 PM EDT
9.75
+0.27 (2.85%)
After-hours: Aug 21, 2026, 7:34 PM EDT
BioAge Labs Revenue
BioAge Labs had revenue of $2.45M in the quarter ending June 30, 2026, with 1.62% growth. This brings the company's revenue in the last twelve months to $10.36M, up 168.06% year-over-year. In the year 2025, BioAge Labs had annual revenue of $9.00M.
Revenue (ttm)
$10.36M
Revenue Growth
+168.06%
P/S Ratio
42.02
Revenue / Employee
$167,016
Employees
62
Market Cap
435.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BIOA News
- 16 days ago - BioAge Labs price target lowered to $20 from $23 at Morgan Stanley - TheFly
- 17 days ago - BioAge Labs price target lowered to $21 from $52 at Citi - TheFly
- 17 days ago - BioAge Labs reports Q2 EPS (58c), consensus (62c) - TheFly
- 17 days ago - BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 18 days ago - BioAge Labs Quarterly report: Q2 2026 - Filings
- 18 days ago - BioAge Labs Earnings release: Q2 2026 - Filings
- 23 days ago - BioAge Labs price target lowered to $25 from $36 at Roth Capital - TheFly
- 23 days ago - BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi - TheFly